NCT07036601

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

A Multicenter, Randomized, Double-blind, Placebo-Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of THDBH120 Injection in Overweight or Obese Subjects

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 276 (estimated)
• Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

Conditions

• Overweight or Obese

Interventions

Type	Name	Description
DRUG	THDBH120 injection	Participants received THDBH120 by subcutaneous injection.
DRUG	Placebo of THDBH120 injection	Participants received placebo by subcutaneous injection.

Timeline

• Start date: 2025-01-06
• Primary completion: 2026-02-13
• Completion: 2026-03-11
• First posted: 2025-06-25
• Last updated: 2025-06-25

Locations

1 site across 1 country: China